Tajikistan Medical Device Regulation 2026: Two Prohibitions on State Registration

1. Key takeaways

The law of Tajikistan provides for two categories of situations in which state registration is prohibited. Article 17(5) of Law No. 1893 provides that state registration is prohibited in the following situations: two or more medicines with different compositions produced under the same trade name; and the same medicine produced by the same manufacturer for the same registration certificate holder or owner under different trade names, submitted for state registration as two or more medicines. GRZAN notes: this prohibition list targets duplicate submissions and name confusion, and enterprises must pass this gate first when planning product line naming and multi-brand strategies.

2. Legal basis

3. Expert insights

Insight 1: The legislative purpose of these two prohibitions is to protect the correspondence between names and products. Item 1 regulates one name for multiple products — different compositions under one trade name make it impossible at prescribing, dispensing and traceability stages to determine what a patient actually receives. Item 2 regulates one product under multiple names — the same manufacturer splitting one product into several trade names and filing multiple certificates for the same holder is in substance a repeated occupation of review resources and the creation of market barriers. Together, the two items protect the basic order that one name corresponds to one definite product.

Insight 2: The literal object of the provision is medicines, but its structural logic is also valuable as a reference for medical goods. Both items of Article 17(5) use the word medicines, whereas in the registerable list of Article 17(3), only category 5 concerns parapharmaceuticals. The interpretation of GRZAN is that the regulatory focus of this prohibition lies in the management of medicine trade names, but enterprises should still treat it as a reference when planning multi-brand strategies for medical devices — because Article 17(12) authorizes the Ministry of Health to develop registration procedures for medical goods, and the procedural documents may well absorb the same prohibition logic.

Insight 3: The distinction between Article 1, item 32 and item 33 is the foundation of naming compliance. Item 32 defines the trade name as determined by the developer, the registration certificate holder or the manufacturer; item 33 defines the international nonproprietary name as recommended by the World Health Organization. For medicines, these two naming systems run in parallel. For devices, although there is no international nonproprietary name layer, the attribution of the power to determine the trade name is equally important — it determines who may define the product name in the registration dossier, and in turn who must apply when the name is changed.

Insight 4: Prohibition of registration and exemption from registration are two different mechanisms that must not be confused. Article 17(4) means registration is not required; Article 17(5) means registration is not allowed. The former is an exemption; the latter is a prohibition. When assessing whether a product can enter Tajikistan, an enterprise should first check paragraph 4 (whether an exemption is available), then paragraph 5 (whether registration is prohibited), and only then proceed to the assessment of the ordinary registration pathway.

4. Practical recommendations

1. Run a name-conflict self-check at the product line planning stage. GRZAN recommends establishing a trade name ledger for the Tajikistan market and checking item by item whether different compositions share one name or one product carries several names, paying particular attention to consistency with names used in other markets.
2. Reassess multi-brand strategies. If an enterprise uses multiple brands to cover different channels in other markets, it must assess before entering Tajikistan whether this falls under Article 17(5), item 2. The experience of GRZAN is that a scheme of several names for one product under the same holder carries significantly higher risk in Tajikistan than in other markets.
3. Clarify the attribution of naming authority in the registration dossier. Under Article 1, item 32, specify in the authorization letter and the registration application the party that determines the trade name, avoiding later disputes over the responsible entity when the name changes.
4. Turn Article 17(4) and Article 17(5) into two separate lists. One exemption list and one prohibition list, ticked item by item at the initiation of every SKU, serving as the first gate of registration feasibility assessment.

5. Verification checklist

• □ Compared item by item against the two prohibition situations of Article 17(5)
• □ Established a trade name ledger for the Tajikistan market and completed the conflict self-check
• □ Assessed whether the multi-brand strategy falls under the one product under multiple names prohibition of item 2
• □ Clarified the party determining the trade name in the authorization letter and registration application (Article 1, item 32)
• □ Distinguished the two mechanisms of exemption from registration (paragraph 4) and prohibition of registration (paragraph 5)
• □ Confirmed whether the medical goods registration procedure documents absorb the same prohibition logic (Article 17(12))
• □ Completed the first-gate registration feasibility assessment for all SKUs

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com